-SEC Filing
Analyst Thinks This Company’s Bone Marrow Cancer Treatment Can ‘Transform Paradigm’
SVB Leerink initiated coverage on CTI Biopharma Corp (NASDAQ:CTIC) with an Outperform rating and a $13 price target. CTIC is a commercial-stage…
Related Posts
What’s Going On With Shares Of Bitcoin Miner Hut 8 Monday?
Hut 8 Corp (NASDAQ: HUT) shares are trading flat.
WillScot Mobile Mini Sees FY23 Revenue $2.325B-$2.475B Vs $2.39B Est
2023 Outlook 2, 3, 4
This guidance is subject to risks and uncertainties, including those described in "Forward-Looking Statements" below.
$M
2022 Results
Excluding
Jabil Acquires Retronix, Promotes Eco-Friendly Manufacturing
Jabil Inc. (NYSE: JBL) expands its commitment to sustainability by acquiring Retronix, a provider in the reclamation and refurbishment of electronic components.